Financial Utilization - The total amount utilized from the global offering proceeds as of December 31, 2021, was HKD 575.15 million[2] - HKD 145.02 million was allocated for the development and commercialization of core products and other major products under research[2] - HKD 155.00 million was used for preclinical research and clinical trial preparations for other products in the pipeline[2] - HKD 27.98 million was invested to enhance R&D capabilities to enrich the product pipeline[2] - HKD 157.97 million was directed towards potential strategic acquisitions, investments, partnerships, and licensing opportunities[2] - HKD 89.18 million was allocated for working capital and other general corporate purposes[2] Stock Options - The company granted a total of 7,801,386 stock options under the stock option plan, with a fair value of approximately HKD 53.12 million on the grant date[8] - The exercise price of the granted stock options was set at HKD 15.97, while the closing price before the grant date was HKD 15.26[8] - The remaining term of the stock option plan is approximately 8 years as of the report date[8] Strategic Goals - The company aims to utilize the proceeds for potential product licensing and acquisition opportunities in the field of mitral valve replacement and repair treatments[5]
沛嘉医疗-B(09996) - 2022 Q3 - 季度财报